Budesonide/formoterol/glycopyrrolate - Pearl Therapeutics

Drug Profile

Budesonide/formoterol/glycopyrrolate - Pearl Therapeutics

Alternative Names: BGF MDI; Budesonide/glycopyrrolate/formoterol; Budesonide/PT 003; Formoterol/budesonide/glycopyrrolate; Formoterol/glycopyrrolate/budesonide; Glycopyrrolate/budesonide/formoterol; Glycopyrrolate/formoterol/budesonide; LAMA/LABA/ICS triple combination - Pearl Therapeutics; PT-003/budesonide; PT-010

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Anti-inflammatories; Antiasthmatics; Antispasmodics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 11 Aug 2017 Pearl Therapeutics initiates enrolment in a phase I trial for Chronic obstructive pulmonary disease in USA (NCT03250182)
  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory filings for Chronic obstructive pulmonary disease in Japan in 2018 (AstraZeneca pipeline, July 2017)
  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory filings for Chronic obstructive pulmonary disease in USA, China and European Union in 2019 (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top